What Are Adaptogens? Definition, Examples and Evidence
Adaptogen is a category with a formal definition, a Soviet research origin and uneven evidence. What qualifies, what does not, and what the trials show.
The Short Answer
An adaptogen is a plant-derived compound proposed to increase the body's non-specific resistance to stress, meaning it improves tolerance of a broad range of stressors rather than acting on one system. The term was coined in 1947 by the Soviet toxicologist Nikolai Lazarev, and the three formal criteria set out by Israel Brekhman remain the definition in use: the substance must be non-toxic at normal doses, must produce a non-specific increase in resistance to physical, chemical and biological stress, and must have a normalising influence that moves physiology toward baseline regardless of the direction of the deviation. The category is not recognised in most regulatory frameworks, evidence quality varies enormously between the plants grouped under it, and the strongest human data belong to ashwagandha and to Rhodiola rosea.
Where the Category Came From
The concept has an unusual history that explains both its appeal and its looseness.
Lazarev proposed the term while studying compounds that improved the performance of workers under industrial stress, and Brekhman and Dardymov developed the three criteria through work on Eleutherococcus senticosus and Panax ginseng. The research programme was substantial, extended over decades, and was conducted largely in Russian, with much of it published in journals that Western reviewers could not readily assess and under methodological standards that would not now pass review.
The concept then arrived in Western supplement markets stripped of its criteria. "Adaptogen" in commercial use now functions as a marketing category rather than a pharmacological one, and it is applied to plants that were never tested against Brekhman's third criterion, which is the demanding one. A substance that raises a physiological variable is not an adaptogen under the original definition. A substance that raises it when low and lowers it when high is.
That third criterion is also the hardest to demonstrate and the least often tested, which is why the honest position on most commercial adaptogens is that they have not been shown to be adaptogens in the technical sense, whatever else they may do.
The Proposed Mechanism
The mechanistic account that has developed since the 1990s is more specific than "stress resistance" and is genuinely interesting.
Hormetic stress signalling. Adaptogens are proposed to act as mild stressors themselves, engaging the cellular stress response, heat shock proteins, Nrf2-mediated antioxidant defence and DAF-16/FOXO signalling, so the adaptive machinery is primed before the real stressor arrives. This makes them a pharmacological analogue of hormesis, which is the same logic as exercise or heat exposure.
Hypothalamic-pituitary-adrenal axis modulation. Several candidates influence cortisol dynamics, and the interesting claim is about the shape of the curve rather than the level: a blunted peak and faster return to baseline rather than a uniformly lower value. Human evidence for this specific pattern exists for ashwagandha and is thinner elsewhere.
Neurotransmitter and receptor effects. Ashwagandha has GABAergic activity, Rhodiola influences monoamine turnover and both have effects that are plainly not confined to a non-specific stress mechanism.
The mechanistic honesty here is that "non-specific resistance" was a phenomenological description from an era with limited molecular tools, and the compounds now grouped under it have distinct, specific and often unrelated pharmacology.
What Has Reasonable Human Evidence
- Ashwagandha, Withania somnifera. The best-evidenced of the group. Multiple randomised controlled trials on perceived stress, cortisol and sleep quality, generally at 300 to 600 mg daily of a root extract standardised to withanolides, over eight to twelve weeks. Effect sizes on stress scales are moderate. Trials on strength, testosterone and thyroid markers exist and are smaller and more heterogeneous. Cautions matter: rare cases of liver injury have been reported, it is contraindicated in pregnancy, it may raise thyroid hormone output which is consequential in existing thyroid conditions, and it has immunostimulatory activity relevant alongside immunosuppressive therapy.
- Rhodiola rosea. Reasonable evidence for reduced fatigue in mentally demanding tasks and in physician shift work, typically 200 to 600 mg daily of extract standardised to rosavins and salidroside. Effects appear more consistent for fatigue than for mood. It can be activating, so morning dosing is standard.
- Panax ginseng. Long history, extensive but methodologically mixed literature, with the most consistent findings on cognitive performance and fatigue. Interaction profile includes anticoagulants and antidiabetic medication.
- Eleutherococcus senticosus. One of the two original Brekhman compounds, with a modern trial literature that is surprisingly thin given its foundational role.
- Schisandra chinensis, Ocimum tenuiflorum, Cordyceps and others. Traditional use, plausible mechanisms, and human trials that are small, short and frequently industry-conducted.
What Is Weak in This Category
Four problems recur across adaptogen research and are worth recognising before reading any individual claim.
Extract heterogeneity. "Ashwagandha 500 mg" specifies almost nothing. Root against whole plant, extraction solvent, withanolide percentage and the specific branded extract used in a trial all matter, and a product matching a trial's dose while differing in preparation is not the same intervention.
Subjective endpoints. Perceived stress and fatigue scales are the primary outcomes in most of this literature, and they are the endpoints most responsive to expectation. Blinding is essential and not always convincing when a compound has noticeable acute effects.
Short duration. Eight to twelve weeks is typical. Adaptogens are frequently taken for years, and there is essentially no long-term safety or efficacy data at that exposure.
Publication and sponsorship pattern. A substantial share of positive trials are conducted by or with extract manufacturers, and effect sizes in independent replications tend to be smaller.
How to Use the Category Practically
The category label is not a reason to take anything. The individual compound's evidence is, and that means reading past the word.
Four rules follow. Match the preparation to the trial, not just the dose, which in practice means using the branded extract a trial used when one exists. Choose by the specific endpoint rather than by the category, since ashwagandha for perceived stress and sleep and Rhodiola for mental fatigue are different decisions with different evidence. Assume a defined trial period with an explicit assessment point, because these are compounds with subjective endpoints and no biomarker, so an eight-week window with a before-and-after measure is the only way to know anything. And run the interaction check seriously: this class includes thyroid, immune, glycaemic and anticoagulant interactions, and the herbal framing tends to suppress the caution that a pharmacological framing would produce.
The honest summary of the whole category: two of these plants have moderate evidence for modest effects on subjective stress and fatigue outcomes over a few months, the classification they share is historical rather than pharmacological, and neither the mechanism nor the long-term picture is settled.
The AEONNN Perspective
Adaptogens map mainly to Hormonal Optimization and Vitality, Pillar 2, and to Cognition and Neuroprotection, Pillar 5, and they are a case where AEONNN's Evidence Levels do more work than the compound descriptions do. Ashwagandha for perceived stress sits at Level A or B depending on endpoint; the same plant for testosterone sits lower; most of the rest of the category sits at Level C.
The Quality layer of the Database Matrix matters unusually much here, because extract standardisation is the difference between a product that matches a trial and one that merely shares a plant name. This is exactly the layer that a supplement label cannot supply and that Apothecary is built to evaluate independently when a member moves from an Element to a specific product.
The Safety layer carries the interaction burden, which in this class is larger than the herbal framing suggests: thyroid output, immune activity, glycaemic control and anticoagulation are all in scope, and Insight Protocol will not surface an adaptogen recommendation without the medication review that the pharmacological profile warrants.
Pillar Matrix mapping
Hormonal Optimization and Vitality, Cognition and Neuroprotection
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Safety Layer (DrugBank, FAERS)
- Regulatory Layer (EFSA, FDA, EMA)
Frequently Asked
What are adaptogens in simple terms?
Plant compounds proposed to increase the body’s general resistance to stress rather than acting on one specific system. The formal definition requires three things: non-toxic at normal doses, a non-specific increase in stress resistance, and a normalising effect that moves physiology toward baseline in either direction.
Who defined the term adaptogen?
Nikolai Lazarev coined it in 1947, and Israel Brekhman and Igor Dardymov set out the three criteria still in use, working on Eleutherococcus senticosus and Panax ginseng. The category is a mid-century Soviet research construct rather than a modern pharmacological class.
Which adaptogens actually have evidence?
Ashwagandha has the strongest human trial base, mainly for perceived stress, cortisol dynamics and sleep quality at 300 to 600 mg daily of a standardised root extract. Rhodiola rosea has reasonable evidence for mental fatigue. The rest of the category is considerably thinner.
Do adaptogens lower cortisol?
Some influence cortisol dynamics, and the interesting claim is about the shape rather than the level: a blunted peak and faster return to baseline. Human evidence for that specific pattern exists for ashwagandha and is thin for most others.
Are adaptogens safe?
Most are well tolerated at trial doses over the eight to twelve weeks typically studied, and the interaction profile is larger than the herbal framing suggests. Ashwagandha has rare reports of liver injury, is contraindicated in pregnancy, may raise thyroid hormone output and has immunostimulatory activity.
How long should you take an adaptogen?
Trial durations are typically eight to twelve weeks, and long-term data are essentially absent. A defined trial period with a before-and-after assessment is the only way to establish whether a compound with subjective endpoints is doing anything.
Is adaptogen a regulated term?
No. It is not recognised as a pharmacological class in most regulatory frameworks, and in commercial use it functions as a marketing category applied to plants that were never tested against the original criteria.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.